Alnylam Pharmaceuticals shares are trading higher after the company announced results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated amyloidosis with cardiomyopathy.
ALNYSeptember 8, 2022
Read more →Alnylam Shares Detailed Patisiran Data From Rare Disease Study
ALNYAlnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
September 8, 2022
Read more →Alnylam Announced APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Met Primary Endpoint, First Secondary Endpoint
ALNYSeptember 8, 2022
Read more →Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
ALNYMay 2, 2022
Read more →HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $430
ALNYMay 2, 2022
Read more →Expert Ratings for Alnylam Pharmaceuticals
ALNYOver the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
April 29, 2022
Read more →BMO Capital Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $166
ALNYApril 29, 2022
Read more →Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $211
ALNYApril 29, 2022
Read more →Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $170
ALNYApril 29, 2022
Read more →SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $96
ALNYApril 29, 2022
Read more →Recap: Alnylam Pharmaceuticals Q1 Earnings
ALNYAlnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q1 earnings results on Thursday, April 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
April 28, 2022
Read more →Alnylam Pharmaceuticals Q1 EPS $(1.49) Beats $(1.84) Estimate, Sales $186.87M Up From $135.77M YoY
ALNYApril 28, 2022
Read more →